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Abstract
In the most common form of stem cell leukemia (SCL)
gene rearrangement, an interstitial deletion of 82 kb
brings SCL under the control of regulatory elements
that normally govern expression of the ubiquitously
expressed SCL interrupting locus (SIL) gene, which is
located directly upstream of SCL. To investigate the
effect of this fusion in a mouse model, a bacterial
artificial chromosome (BAC) clone containing both
human SIL and SCL genes was isolated, and loxP sites
were inserted into intron 1 of both the SIL and SCL
genes, corresponding to the sites at which recombina-
tion occurs in humanT-cell acute lymphocytic leukemia
patients. This BAC clone was used to generate trans-
genic SILloxloxSCL mice. These transgenic mice were
subsequently bred to Lck-Cre mice that express the
Cre recombinase specifically in the thymus. The BAC
transgene was recombined between the two loxP sites
in over 50% of the thymocytes from SILloxloxSCL/Cre
double-transgenic mice, bringing the SCL gene under
the direct control of SIL regulatory elements. Aberrant
SCL gene expression in the thymus was verified by re-
verse transcription–polymerase chain reaction. Using
FACS analysis, we found that mice carrying both
SILloxloxSCL and Cre transgenes have increased
CD4/CD8 thymocytes compared with transgene-
negative mice. In the spleen, these transgenic mice
show amarked reduction in the number of mature CD4+
or CD8+ cells. These results demonstrate that condi-
tional activation of SCL under control of SIL regulatory
elements can impair normal T-cell development.
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Introduction
Activation of the stem cell leukemia (SCL) (also known as
T-cell acute lymphoblastic leukemia 1 (TAL-1 or TCL5 )
transcription factor is a frequent gain-of-function mutation
in pediatric T-cell acute lymphocytic leukemia (T-ALL) [1,2].
SCL is normally expressed in hematopoietic cells, endo-
thelium, and the central nervous system, and has been
shown to be important for blood vessel formation, endothelial
development, and the control of normal hematopoiesis [3–6].
Mice with an SCL null genotype are nonviable, but can be
rescued by the human SCL locus [7].
Normally, expression ofSCL in the thymus is restricted to the
DN1–DN2 subset of immature CD4/CD8 thymocytes [8].
However, in the context of T-ALL, chromosomal translocations
involving the SCL gene and chromosomes 3, 5, 7, and 14 have
been associated with T-ALL and lead to unscheduled SCL
expression [5,9–11]. In addition to the aforementioned chro-
mosomal translocations, the most common event that deregu-
lates SCL expression in T-ALL patients is an 82-kb interstitial
deletion that occurs in approximately 25%of patientswith T-ALL
[2,5,12] and replacesSCL 5V regulatory sequenceswith those of
an upstream gene, known as SCL-interrupting locus (SIL) [1,2].
Attempts to model human T-ALL in mice have met with
variable success. In two independent studies, expression of
a full-length SCL gene under the control of the Lck promoter
led to T-ALL at an advanced age in a fraction at Lck-SCL
transgenic mice [13,14]. In contrast, other studies showed that
deregulated SCL expression alone did not cause T-cell tumors
[15–17]. The reasons for varying results among different
studies are not clear, but may be due to differences in mouse
strains, promoters used, or integration sites. The collective
observations that T-ALL occurred at an advanced age, with
incomplete penetrance, suggested that additional events were
required to produce T-ALL in these mice. Indeed, several reports
have indicated that aberrant SCL expression, in collaboration
with activation of CKIIa, LMO1, or LMO2, leads to the de-
velopment of aggressive T-cell malignancies in transgenic mice
at an early age with a high degree of penetrance [14,16–19].
Transgenic mice that express either a full-length or an
amino-terminal truncated SCL driven by aSIL promoter showed
bony abnormalities and growth retardation, but did not develop
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T-cell malignancies [17].However, when crossed with
mice that overexpress LMO1 in the thymus, these double-
transgenic mice formed aggressive T-cell malignancies with
a high degree of penetrance at an early age [17,19]. Inter-
estingly, abnormal T-cell development was noted in SCL/
LMO1 double-transgenic mice before the onset of malig-
nancy, whereas no abnormal immunophenotype for T-cell
development was detected in mice transgenic only for SCL
or LMO1 [8,19]. Consistent with these results, other groups
also failed to detect a premalignant perturbation of T-cell
differentiation in Lck-SCL or CD2-SCL mice before develop-
ment of leukemia [13,14,16].
We previously demonstrated that SCL could inhibit E2A
activity in a dose-dependent fashion in vitro [8,19]. We
considered the possibility that misexpression of SCL under
the control of SIL regulatory elements [17] did not lead to
T-ALL in mice because the levels of SCL were insufficient to
inhibit E2A (or the closely related HEB protein). Because high
levels of SCL expression under the control of SIL regulatory
elements seemed to be toxic to the developing embryo
(reference 17 and unpublished data), we used Cre-loxP tech-
nology to generatemice that would conditionally expressSCL
under the control of SIL regulatory elements. Moreover, we
reason that including additional SIL regulatory sequences
might lead to higher levels of SCL expression compared
to the 2.3 kb of SIL promoter sequence used for the pSIL/
SCL mice [19].
Materials and Methods
Generation of Bacterial Artificial Chromosome Clone
and SILloxloxSCL Transgenic Mice
We isolated a bacterial artificial chromosome (BAC) clone
containing both humanSIL andSCL genes as well as 47 kb of
sequence immediately 5V of SIL, and used ‘‘recombineering’’
[20] to introduce loxP sites into intron 1 of bothSIL (nucleotide
47491426 of human chromosome 1; National Center for
Biotechnology Information [NCBI] build 35 by the Inter-
national Human Genome Sequencing Consortium, May
2004) and SCL (nucleotide 47409602), corresponding to
the sites at which recombination occurs in human T-ALL
patients. This BAC clone was linearized with PI-SceI and
injected into fertilized FVB/N embryos to generate transgenic
SILloxloxSCL mice.
Genomic DNA Polymerase Chain Reaction, Southern
Blotting, and DNA Sequencing
All polymerase chain reaction (PCR) amplifications, un-
less otherwise indicated, were performed by using PCR
SuperMix High Fidelity enzyme and buffers (Invitrogen,
Carlsbad, CA). PCR primer sequences and annealing tem-
perature are listed in Table 1. Mouse tail DNA was extracted
for PCR analyses as follows. Two millimeters of tail was cut
and added to 600 ml of 50 mmol/l NaOH, heated to 95jC
for 1 hour, and neutralized with 50 ml of 1 mol/l Tris (pH 8).
One microliter of this crude DNA preparation was used for
mouse genotype analysis. For the human SIL gene, the
primers were SIL5VF and 3V-SILR; for the human SCL gene,
the primers were 3VSCLF and 3VSCLR. Cre-positive and
-negative mice were identified by PCR using primers
cre1083F and cre1085R. To identify SIL-SCL recombination
at the LoxP site, sequences in the first intron of the SIL gene
(SIL5VF) and the first intron of the SCL gene (SCLR-TARG)
were used for PCR primers. To verify DNA quality, we
amplified the mouse Scid locus by using primers SCIDA
and SCIDB.
PCR products were cloned into the pGEM-T easy vector
(Promega, Madison, WI) and transformed into DH-5a cells.
Plasmid DNA was extracted (Qiagen, Valencia, CA) and
sequenced (Napcore, The Children’s Hospital of Philadel-
phia). All procedures were performed following the manu-
facturers’ protocols.
For Southern blot studies, 10 mg of genomic DNA iso-
lated from mouse tissue by use of a proteinase K/SDS
salting out procedure [21] was digested with restriction
enzymes and size fractionated using a 0.8% agarose gel.
The DNA fragments were transferred to nitrocellulose mem-
branes and hybridized to 32P-labeled probes. Probes used
included a previously described human TCR Cb2 probe
[17], a human SIL exon 1 probe (nucleotides 47491736
to 47492065, human chromosome 1; NCBI build 35 by the
International Human Genome Sequencing Consortium, May
2004) [22,23], and a human SCL probe from the 3V untrans-
lated region (929 bp, nucleotides 47394123 to 47393194,
human chromosome 1; NCBI build 35 by the International
Human Genome Sequencing Consortium, May 2004). Frag-
ments were labeled with 32P by using Ready-To-Go DNA
labeling beads (Amersham Bioscience, Piscataway, NJ).
Hybridization was performed as previously described [21].
The washing conditions were 0.1%SDS/2 SSC at 42jC for
20minutes and 0.1%SDS/0.1SSC at 52jC for 40minutes.
Reverse Transcription–PCR and Semiquantitative
Reverse Transcription-PCR
Total RNA was isolated using Trizol reagent and the
manufacturer’s (Invitrogen) recommended protocol. To
Table 1. PCR Primers.
Name Sequence (5V > 3V) Annealing
Temperature
(jC)
SIL5VF (forward) GCCCTGTAGTGGGTTCCGCCC 60
3V-SILR (reverse) TCCAGTCAAACTGAACTACTTGC 60
3Vof SCLF (forward) GGCCTGGTGGGGAGGAGACAGC 60
3Vof SCLR (reverse) GATACATACAACTGTCCCAGCC 60
cre1083F (forward) GCGGCATGGTGCAAGTTGAATAA 55
cre1085R (reverse) GTGAAACAGCATTGCTGTCACTT 55
SCLR-TARG
(reverse)
GACACCACCCAAACACAGTCGC 56
SCIDA (forward) GGAAGAGTTTTGAGCAGACAATG 54
SCIDB (reverse) CATCACAAGTTATAACAGCTGGG 54
SILexon1 (forward) GCTCCTACCCTGCAAACAGA 60
SCLexon3 (reverse) GGCATATTTAGAGAGACCG 60
Tal1 (forward) ATGGTGCAGCTGAGTCCTCC 52
Tal1 (reverse) TCTCATTCTTGCTGAGCTTC 52
b-Actin F (forward) GTGGGCCGCTCTAGGCACCAA 58
b-Actin R (reverse) CTCTTTGATGTCACGCACGATTTC 58
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eliminate potential contamination of genomic DNA, all total
RNA samples were treated with 2 U DNAse for 30 minutes
(Ambion, Austin, TX). First-strand cDNA was synthesized
from 1 mg of DNAse-treated RNA by using SuperScript
First-Strand Synthesis System for reverse transcription
(RT)-PCR (Invitrogen), following themanufacturer’s protocol.
Controls without reverse transcriptase were performed in
all reactions to detect possible contamination of genomic
DNA. PCR amplification of b-actin was used to verify that
intact mRNA was present.
The primers for the SIL-SCL fusion mRNAwere SILexon1
and SCLexon3. RT-PCR products were cloned into plasmid
vectors and sequenced as described above. Semiquan-
titative RT-PCR was performed by serial 10-fold dilution
of cDNA templates (1, 0.1, 0.01, and 0.001 for
each sample).
Immunophenotype Analysis
Cells from thymus and spleen were minced and homoge-
nized using a loose-fitting ground-glass homogenizer as
previously described [19] to generate a single-cell suspen-
sion in RPMI 1640 medium. The cell suspension was filtered
through a cell strainer (BD, Bedford, MA) and treated with
ACK lysing buffer (Biosource, Camarillo, CA) for 10 minutes.
Viable cells (1  106) were used for subsequent antibody
staining. The cells were incubated with 5 ml (0.5 mg/ml) of
rat anti–mouse CD16/CD32 for 20 minutes as a blocking
agent. The single-cell suspension was incubated with 5 ml
(0.2 mg/ml) of fluorescein isothiocyanate– or phycoerythrin-
labeled antibodies (murine CD4, CD8, CD25 or CD 44)
for 30 minutes. All antibodies were purchased from BD
Pharmingen (San Jose, CA). Ten thousand events per sam-
ple were scored using a FACSort flow cytometer (Becton-
Dickinson, San Jose, CA).
Results
Generation of Mice Susceptible to SIL-SCL Recombination
Three founder lines (F1, I2, and H6) that had incorporated
at least one copy of the SILloxloxSCL BAC clone (Figure 1A)
were identified by PCR analyses. We used Southern blot
analysis of the BAC clone integration site to identify a
founder that had integrated a single copy of the BAC clone
(Figure 1B) and verified that this line had retained all of the
SIL and SCL genomic sequences by PCR. To determine
whether Cre-loxP–mediated SIL-SCL recombination could
be achieved in vivo, we crossed offspring of the H6 founder,
which had integrated a single copy of the SILloxloxSCL BAC
clone, to mice that expressed the Cre recombinase under
the control of the Lck promoter to produce SILloxloxSCL+/
Cre+ double-transgenic mice.
We used genomic DNA PCR to verify that recombina-
tion between the SIL and SCL loci had taken place in
SILloxloxSCL+/Cre+ mice. A PCR product of 543 bp could
be identified in thymus, and to a lesser extent in spleen, of
the SILloxloxSCL+/Cre+ mice, but not the control geno-
types, indicating a precise Cre-LoxP–mediated excision of
82 kb (Figure 1C).
To obtain a more quantitative estimate of the relative
proportion of SILloxloxSCL alleles in the rearranged versus
nonrearranged configuration, we used SIL exon 1 as a probe
to detect recombination in the transgenic mice through
Southern blot analysis. In SILloxloxSCL+/Cre+ mice, the
ratio of recombined to unrecombined products is approxi-
mately 1 as seen in Figure 1D. As anticipated from the
PCR results, these recombination events occurred only in
the thymus and spleen of SILloxloxSCL+/Cre+double-
transgenic mice. The sequence of the PCR product from
thymus shows a SIL-SCL genomic fusion, with intervening
LoxP sequence (Figure 1E ).
SILloxloxSCL+/Cre+ Double-Transgenic Mice Do Not
Develop T-Cell Tumors
Using semiquantitative RT-PCR analysis, we demon-
strated that SILloxloxSCL+/Cre+ mice that have undergone
Cre-LoxP–mediated recombination in the thymus express
f10- to 100-fold higher levels of SCL expression than
those of the pSIL/SCL transgenic mice that express an SCL
cDNA from 2.3 kb of SIL 5V regulatory sequence [19] (Fig-
ure 2). We followed a cohort of SILloxloxSCL+/Cre+ mice for
19 months and compared them with three control groups:
positive for either the SILloxloxSCL or theCre only and nega-
tive for both transgenes. Their survival curves were similar;
none of 14 double-transgenic mice or 46 control mice from
this cohort developed T-cell malignancy (Figure 3).
Mice Transgenic for SIL-SCL and Cre Demonstrate
Impaired T-Cell Differentiation
Because SILloxloxSCL+/Cre+ double-transgenic mice
expressed higher levels of SIL-SCL fusion mRNA in the
thymus than did the pSIL/SCL mice (Figure 2), we searched
for evidence that these higher levels of ectopically expressed
SCLmight affect T-cell growth and differentiation. To achieve
this purpose, we performed T-cell subset analyses on the
thymus and spleen of mice aged 6 to 15 months.
The SILloxloxSCL+/Cre+ mice showed a variable, and
in some cases quite dramatic, increase in CD4/CD8
(DN) cells and a corresponding decrease in CD4+/CD8+
(DP) cells in the thymus (Figures 4 and 5A). On average,
the SILloxloxSCL+/Cre+mice had 30.3 ± 17.4% DN cells and
44.5 ± 19.9% DP cells, compared with control mice, which
had 8.0 ± 2.5% DN and 69.8 ± 8.5% DP cells (P < .001).
Consistent with the thymocyte data, mice with decreased
DP cells in the thymus had decreased percentages of mature
single positive (SP) CD4+ (P < .01) and CD8+ (P < .05) cells in
the spleen, compared with wild-type controls (Figures 4 and
5B). In addition, we searched for immature CD44+CD25
cells in the thymus of some SILloxloxSCL+/Cre+ mice. As
shown in Figure 5C, SILloxloxSCL+/Cre+ mice had a marked
increase in this population compare with wild-type controls.
To determine whether the SILloxloxSCL+/Cre+ mice had
a clonal or oligoclonal expansion of thymocytes, genomic
DNA from SILloxloxSCL+/Cre+ mice was digested with SstI,
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blotted, and hybridized with a TCR Cb2 probe. No clonal
TCR gene rearrangements were detected in SILlox-
loxSCL+/Cre+ transgenic mice nor in the control wild-type or
single-transgenic mice (data not shown).
Discussion
The fusion of the SIL gene promoter region with the down-
stream SCL gene is a common rearrangement detected in
patients with T-ALL [2,12,22]. Surprisingly, pSIL/SCL mice
Figure 1. Generation and characterization of SILloxloxSCL mice. (A) Top panel shows the human SIL (18 exons), SCL genes (8 exons), and the introduced Lox P
sites in the regions of intron 1. Not all SIL exons are shown. Middle panel shows the fusion of genomic DNA. Two arrows indicate the primers used for a detection of
fusion SILloxSCL DNA. Bottom panel shows the fusion mRNA that is generated between exon 1 of SIL and exon 3 of SCL in double-transgenic mice. Two arrows
indicate the primers used for a detection of SIL-SCL fusion mRNA. (B) Detection of SILloxloxSCL BAC clone integration site(s) by Southern blot. Genomic DNA
from F1 offspring of founders I2, H6, or F1 was digested with XbaI or NsiI and hybridized to a probe from the SCL 3 V untranslated region located at one terminal of
the BAC clone. Variable-sized fragments representing unique integration sites can be seen. A cross-hybridizing band is seen in the NsiI digest at 9.4 kb. Mouse
numbers are indicated, as is transgene status (+ or ) (C) SIL-SCL genomic fusion can be detected in mice 1204 and 1198 by PCR. Mice 1202, 1203, and H2O
were negative controls. PCR amplification of the scid locus was used as a DNA quality control. T, thymus; S, spleen; L, liver. (D) Detection of SIL-SCL fusion by
Southern blot analysis of SstI-digested genomic DNA. 2385T, thymus from mouse without the SILloxloxSCL transgene. 2386T, 2386S, 2386K; thymus, spleen, and
kidney from SILloxloxSCL+/Cre+ mouse. E, endogenous murine SIL; R, recombined SIL-SCL fusion; UR, unrearranged SILloxloxSCL transgene. (E) Nucleotide
sequences of fusion SILloxSCL genomic DNA.
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that express SCL under the control of SIL regulatory ele-
ments [19] did not develop T-ALL, nor did these mice show
any abnormalities in T-cell differentiation. However, when
crossed to transgenic mice that expressed LMO1 in the
thymus, the SCL/LMO1 double-transgenic mice developed
T-ALL preceded by abnormalities in thymocyte differentia-
tion, including an oligoclonal expression of DN cells [17,19].
To determine if an SCL expression construct that more
closely resembled the situation seen in humanT-ALL patients
could cause T-ALL, we isolated a human BAC clone that
contained both the human SIL and SCL genes, and intro-
duced LoxP sites into intron 1 of theSIL andSCL genes at the
sites where recombination occurs in human T-ALL patients
[12,24]. This clone was then used to generate transgenic
SILloxloxSCL mice. After crossing the SILloxloxSCL mice
to Lck-Cre mice, which expressed the Cre recombinase in
the thymus, we were able to detect a SILloxSCL genomic
fusion and a SIL-SCL fusion mRNA, thus mimicking the
common form of SCL gene activation seen in T-ALL patients.
Of note, although it is well established that the Cre recombi-
nase efficiently catalyzes recombination between LoxP sites
located less than 5 kb apart [25] and that the Cre recombi-
nase can catalyze rare recombination between LoxP sites
on different chromosomes [26], we show here that Cre-
mediated recombination can efficiently act over a distance
of 82 kb and cause recombination of approximately half of
the SILloxloxSCL alleles.
In our previous studies, both T-ALL and abnormal T-cell
development were detected in SCL/LMO1 double-transgenic
mice, but not in pSIL/SCL transgenic mice that expressed a
full-length SCL protein [19]. Using a semiquantitative RT-PCR
assay, we show that SILloxloxSCL/Cre transgenic mice have
higher levels of SCL expression than those of pSIL/SCL
transgenic mice. This difference may be due to incorporation
of additional SIL regulatory elements (f47 kb of sequences
5V of SIL exon 1), which may affect both timing and level of
SCL expression in transgenic mice. Using Lck to direct SCL
expression in the mouse thymus, two laboratories have in-
duced T-ALL in mice but did not observe any evidence of a
premalignant perturbation of T-cell development [13,14].
Four populations of developing T-cells can be identified
through immunophenotype analysis: CD4CD8 (DN), the
CD4+CD8+ (DP) and CD4CD8+ (CD8 SP), or CD4+CD8
(CD4 SP). The DN population can be further subdivided into
CD44+CD25 (DN1), CD44+CD25+ (DN2), CD44CD25+
(DN3), and CD44CD25 (DN4) stages [27]. To determine
whether expression of the SIL-SCL fusion generated in our
current study affects T-cell development, we performed
FACS analysis of thymocytes from SILloxloxSCL+/Cre+
mice. The fraction of DN thymocytes in SILloxloxSCL+/Cre+
mice was significantly increased compared with those of
the control groups. Furthermore, we noted an increase in
the percentage of immature DN1 cells in the thymus of
SILloxloxSCL+/Cre+ transgenic mice, which were not de-
tected in either SILloxloxSCL/Cre or SILloxloxSCL+/Cre
mice, indicating impaired T-cell development at the DN1
stage. We also found that CD4 SP and CD8 SP cells were
decreased in the spleen of SILloxloxSCL+/Cre+ mice, con-
sistent with the decrease in DP cells seen in SILloxloxSCL+/
Cre+ mice thymus.
Figure 2. Higher level SCL expression in SILloxloxSCL+/Cre+ mice than pSIL/SCL mice. Mouse 5026, positive for both SILloxloxSCL and Cre transgenes, has a
higher level of SCL expression than a pSIL/SCL transgenic mouse (4027); mouse 5029 is negative for both SILloxloxSCL and Cre transgenes. T, S, and K are
thymus, spleen, and kidney, respectively. The cDNA templates were diluted to 1, 0.1, 0.01, and 0.001 times in PCR reactions.
Figure 3. SILloxloxSCL+/Cre+ mouse survival curve. Mice of the indicated
genotypes were followed for 19 months and euthanized when morbid. There
was no difference in survival for any group.
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Tumorigenesis is a multistep process [28]. Although the
development of T cells was impaired in SILloxloxSCL+/Cre+
mice, we did not detect any clonal TCR gene rearrange-
ments in these mice, suggesting that there was no clonal or
oligoclonal expansion. However, because TCR gene re-
arrangement typically occurs in the DN2 population, it is
possible that clonal expansion, undetectable by TCR gene
rearrangement, has occurred in the samples with a predomi-
nant DN1 population. None of the 14 mice with both the
SIL-SCL and the Cre transgenes developed T-cell malignan-
cies over a 19-month observation period. Despite the higher
level of SCL expression and perturbations of thymocyte
development observed in these mice, aberrant expression
of SCL in the thymus was insufficient to induce leukemia.
There are several possible explanations for the lack of
leukemic transformation in the SILloxloxSCL+/Cre+mice that
had undergone SIL-SCL recombination. First, the lack of
leukemic transformation may be due to subtle, undetected
Figure 4. Aberrant T-cell differentiation in SILloxloxSCL+/Cre+ mice. Thymocytes and splenocytes from SILloxloxSCL+/Cre+ (closed circles) or SILloxloxSCL or
SILloxloxSCL+/Cre mice (open circles) stained with CD4 + CD8. The number of samples analyzed is indicated. The means are indicated with a solid line. *P <
.001; **P < .01; ***P < .05.
Figure 5. FACS profiles demonstrating aberrant T-cell development. Thymocytes (A) and splenocytes (B) from clinically healthy mice with the indicated genotype
were stained with CD4 and CD8. Note the increased DN population in the SILloxloxSCL+/Cre+ thymocytes, and decreased SP population in SILloxloxSCL+/Cre+
splenocytes. (C) Thymocytes from above mice were stained with CD44 and CD25; note increased CD44+CD25 population in SILloxloxSCL+/Cre+ sample.
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mouse strain differences. Second, the SCL transgene may
not be expressed at a ‘‘leukemogenic’’ point in thymocyte
differentiation, as SCL expression is dependent on expres-
sion of the Cre recombinase under the control of Lck pro-
moter. Lastly, it is possible that the SIL-SCL fusion is a
primary oncogenic event and requires additional events for
complete leukemic transformation [13,14].
In summary, we designed and generated a genetic event
that faithfully recapitulates the interstitial deletion leading to
SIL-SCL fusion gene seen in human T-ALL patients. We
demonstrated that expression of SCL, under the control of
SIL regulatory elements, can perturb normal T-cell develop-
ment, whichmight provide an abnormal environment in which
additional genetic events occur, and result in complete ma-
lignant transformation.
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